EQS-News
Heidelberg Pharma and Partner Magenta to Present Initial Clinical Data on their Antibody Drug Conjugates at the ASH Annual Meeting 2022 - Seite 2
HDP-101 is a BCMA antibody-Amanitin conjugate for the treatment of relapsed or refractory multiple myeloma, a bone marrow cancer with high unmet medical need. The first part of the ongoing trial is a Phase I dose escalation study to determine an optimal and safe dose of HDP-101 for the Phase II part of the study. It is planned to treat up to 36 patients who will receive HDP‑101 intravenously every 3 weeks. During this part of the trial, tolerability of different dose levels will be evaluated.
Oral presentation from Heidelberg Pharma’s licensing partner Magenta
Presentation details
Abstract #874
Session: 701. Experimental Transplantation: Basic and Translational: Poster III
Time and location: Monday, December 12, 2022, 3.30pm CST
Lesen Sie auch
Poster presentations from Heidelberg Pharma’s licensing partner Magenta
Presentation details
Abstract #4592
Session: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster I
Time and location: Monday, December 12, 2022, 6:00-8:00 pm CST, Hall D (Ernest N. Morial Convention Center)
All abstracts and further information will be available online on the ASH conference website.
About Heidelberg Pharma's proprietary ATAC technology
Antibody drug conjugates (ADCs) combine the high affinity and specificity of antibodies with the potency of cytotoxic small molecules for the treatment of cancer. ATACs are ADCs whose active ingredient is made up of amatoxin molecules. Amatoxins are small bicyclic peptides naturally occurring in the death cap mushroom. They inhibit mRNA transcription by binding to RNA polymerase II, a mechanism that is crucial for the survival of eukaryotic cells. In preclinical testing, ATACs have been shown to be highly efficacious, overcoming frequently encountered resistance mechanisms and combating even quiescent tumor cells.